Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Michael T SchweizerRoman GulatiTodd YezefskiHeather H ChengElahe MostaghelMichael C HaffnerRadhika A PatelNavonil De SarkarGavin HaRuth DumpitBrianna WooAaron LinPatrick PanlasiguiNerina McDonaldMichael LaiKatie NegaJeannette HammondPetros GrivasAndrew C HsiehBruce MontgomeryPeter S NelsonEvan Y YuPublished in: Prostate cancer and prostatic diseases (2022)
BAT plus olaparib is associated with high response rates and long PFS. Clinical benefit was observed regardless of HRR gene mutational status.